Bremner PR, et al. - Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 μg has been shown to improve lung function and health status, and reduce exacerbations, vs budesonide/formoterol in patients with chronic obstructive pulmonary disease (COPD). In this study, researchers assessed the non-inferiority of single-inhaler FF/UMEC/VI vs FF/VI + UMEC using two inhalers. They found that single-inhaler triple therapy (FF/UMEC/VI) was non-inferior to two inhalers (FF/VI + UMEC) on trough forced expiratory volume in 1 s change from baseline at 24 weeks. Notably, similar outcomes were seen on all other measures of efficacy, health-related quality of life, and safety.